Tranilast treatment decreases cell growth, migration and inhibits colony formation of human breast cancer cells

Experimental and Molecular Pathology

Volumn 90, Issue 1, 2011, Pages 116-122

  Subramaniam, Venkateswaran ^a   Ace, Olga ^a   Prud'homme, Gerald J ^a   Jothy, Serge ^a,b  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Breast cancer; Clonogenicity; Drugs; Proliferation; Therapy; Tranilast

Indexed keywords

CYTOSKELETON PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN MRTF A; REGULATOR PROTEIN; TRANILAST; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER INHIBITION; CARCINOMA CELL; CELL COUNT; CELL MIGRATION; CELL STIMULATION; CELL STRAIN; CELL STRAIN BT 474; CELL STRAIN MDA MB 231; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY;

ANTHRANILIC ACIDS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; COLONY-FORMING UNITS ASSAY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; POLY(ADP-RIBOSE) POLYMERASES;

ANIMALIA;

EID: 78650681544     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2010.10.012     Document Type: Article

References (22)

1. Alimova I.N., Liu B., Fan Z., Edgerton S.M., Dillon T., Lind S.E., Thor A.D. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle 2009, 8:909-915.
2. Anders C., Carey L.A. Understanding and treating triple-negative breast cancer. Oncology (Williston. Park) 2008, 22:1233-1239.
3. Azuma H., Banno K., Yoshimura T. Pharmacological properties of N-(3′, 4′-dimethoxycinnamoyl) anthranilic acid (N-5′), a new anti-atopic agent. Br. J. Pharmacol. 1976, 58:483-488.
4. Bauer K.R., Brown M., Cress R.D., Parise C.A., Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 2007, 109:1721-1728.
5. Carotenuto P., Roma C., Rachiglio A.M., Botti G., D'Alessio A., Normanno N. Triple negative breast cancer: from molecular portrait to therapeutic intervention. Crit. Rev. Eukaryot. Gene Expr. 2010, 20:17-34.
6. Chakrabarti R., Subramaniam V., Abdalla S., Jothy S., Prud'homme G.J. Tranilast inhibits the growth and metastasis of mammary carcinoma. Anticancer Drugs 2009, 20:334-345.
7. Dent R., Trudeau M., Pritchard K.I., Hanna W.M., Kahn H.K., Sawka C.A., Lickley L.A., Rawlinson E., Sun P., Narod S.A. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin. Cancer Res. 2007, 13:4429-4434.
8. Emens L.A., Davidson N.E. Trastuzumab in breast cancer. Oncology (Williston. Park) 2004, 18:1117-1128.
9. Esteva F.J., Hortobagyi G.N. Prognostic molecular markers in early breast cancer. Breast Cancer Res. 2004, 6:109-118.
10. Fong P.C., Boss D.S., Yap T.A., Tutt A., Wu P., Mergui-Roelvink M., Mortimer P., Swaisland H., Lau A., O'Connor M.J., Ashworth A., Carmichael J., Kaye S.B., Schellens J.H., de Bono J.S. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J. Med. 2009, 361:123-134.
11. Goodwin P.J., Ligibel J.A., Stambolic V. Metformin in breast cancer: time for action. J. Clin. Oncol. 2009, 27:3271-3273.
12. Khoury H., Naujokas M.A., Zuo D., Sangwan V., Frigault M.M., Petkiewicz S., Dankort D.L., Muller W.J., Park M. HGF converts ErbB2/Neu epithelial morphogenesis to cell invasion. Mol. Biol. Cell 2005, 16:550-561.
13. Koda A., Kurashina Y., Nakazawa M. The inhibition mechanism of histamine release by N-(3, 4-dimethoxycinnamoyl) anthranilic acid. Int. Arch. Allergy Appl. Immunol. 1985, 77:244-245.
14. Medjkane S., Perez-Sanchez C., Gaggioli C., Sahai E., Treisman R. Myocardin-related transcription factors and SRF are required for cytoskeletal dynamics and experimental metastasis. Nat. Cell Biol. 2009, 11:257-268.
15. Miller K., Wang M., Gralow J., Dickler M., Cobleigh M., Perez E.A., Shenkier T., Cella D., Davidson N.E. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J. Med. 2007, 357:2666-2676.
16. Modi S., D'Andrea G., Norton L., Yao T.J., Caravelli J., Rosen P.P., Hudis C., Seidman A.D. A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancer. Clin. Breast Cancer 2006, 7:270-277.
17. Nie L., Oishi Y., Doi I., Shibata H., Kojima I. Inhibition of proliferation of MCF-7 breast cancer cells by a blocker of Ca(2+)-permeable channel. Cell Calcium 1997, 22(2):75-82.
18. Platten M., Wild-Bode C., Wick W., Leitlein J., Dichgans J., Weller M. N-[3, 4-dimethoxycinnamoyl]-anthranilic acid (tranilast) inhibits transforming growth factor-beta relesase and reduces migration and invasiveness of human malignant glioma cells. Int. J. Cancer 2001, 93:53-61.
19. Shirasawa S., Furuse M., Yokoyama N., Sasazuki T. Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 1993, 260:85-88.
20. Subramaniam V., Li H., Wong M., Kitching R., Attisano L., Wrana J., Zubovits J., Burger A.M., Seth A. The RING-H2 protein RNF11 is overexpressed in breast cancer and is a target of Smurf2 E3 ligase. Br. J. Cancer 2003, 89:1538-1544.
21. Subramaniam V., Chakrabarti R., Prud'homme G.J., Jothy S. Tranilast inhibits cell proliferation and migration and promotes apoptosis in murine breast cancer. Anticancer Drugs 2010, 21:351-361.
22. Wong K., Rubenthiran U., Jothy S. Motility of colon cancer cells: modulation by CD44 isoform expression. Exp. Mol. Pathol. 2003, 75:124-130.